AbbVie (BUE:ABBV) Cyclically Adjusted Revenue per Share: ARS5,053.44 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:ABBV AbbVie Inc BUE:ABBV
67 GF Score
Price ARS38,780.00
GF Value ARS34,303.45
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Cyclically Adjusted Revenue per Share?

AbbVie BUE:ABBV +0.67% 67 Cyclically Adjusted Revenue per Share is ARS5,053.44 as of Jun. 2026. GuruFocus rates BUE:ABBV with a GF Score™ of 67/100 and a GF Value™ of ARS34,303.45 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AbbVie's adjusted revenue per share for the three months ended in Jun. 2026 was ARS14,209.847. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ARS5,053.44 for the trailing ten years ended in Jun. 2026.

During the past 12 months, AbbVie's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AbbVie was 14.30% per year. The lowest was 8.90% per year. And the median was 11.20% per year.

As of today (2026-08-06), AbbVie's current stock price is ARS38780.00. AbbVie's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ARS5,053.44. AbbVie's Cyclically Adjusted PS Ratio of today is 7.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AbbVie was 8.05. The lowest was 4.91. And the median was 6.35.


AbbVie  (BUE:ABBV) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AbbVie's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=38780.00/5053.44
=7.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AbbVie was 8.05. The lowest was 4.91. And the median was 6.35.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AbbVie Cyclically Adjusted Revenue per Share Related Terms


AbbVie Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AbbVie's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Cyclically Adjusted Revenue per Share Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 595.04 2,023.63 3,343.76 4,686.05

AbbVie Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,629.49 4,695.56 4,686.05 4,671.36 5,053.44

BUE:ABBV vs MRK, JNJ, AMGN: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AbbVie's Cyclically Adjusted PS Ratio falls into.


BUE:ABBV
67GF Score
AbbVie Inc BUE:ABBV
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AbbVie's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14209.847/333.9520*333.9520
=14,209.847

Current CPI (Jun. 2026) = 333.9520.

AbbVie Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 58.503 241.428 80.923
201612 66.298 241.432 91.704
201703 62.880 243.801 86.131
201706 71.558 244.955 97.556
201709 76.467 246.819 103.462
201712 92.015 246.524 124.647
201803 100.164 249.554 134.039
201806 131.332 251.989 174.050
201809 200.051 252.439 264.648
201812 208.621 251.233 277.310
201903 206.336 254.202 271.069
201906 248.534 256.143 324.032
201909 319.755 256.759 415.887
201912 349.879 256.974 454.687
202003 360.495 258.115 466.412
202006 433.331 257.797 561.340
202009 539.935 260.280 692.763
202012 633.220 260.474 811.847
202103 660.248 264.877 832.428
202106 744.559 271.696 915.166
202109 789.173 274.310 960.759
202112 844.571 278.802 1,011.636
202203 817.549 287.504 949.629
202206 988.048 296.311 1,113.562
202209 1,158.856 296.808 1,303.881
202212 1,423.378 296.797 1,601.566
202303 1,359.825 301.836 1,504.513
202306 1,878.938 305.109 2,056.560
202309 2,751.978 307.789 2,985.904
202312 2,906.904 306.746 3,164.724
202403 5,849.507 312.332 6,254.417
202406 7,312.660 314.175 7,772.985
202409 7,756.337 315.301 8,215.148
202412 8,588.412 315.605 9,087.680
202503 8,027.162 319.799 8,382.411
202506 10,339.186 322.561 10,704.307
202509 12,090.296 324.800 12,430.968
202512 13,581.556 324.054 13,996.395
202603 11,824.393 330.213 11,958.281
202606 14,209.847 333.952 14,209.847

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ARS5,053.44 mean?
AbbVie (BUE:ABBV) has a Cyclically Adjusted Revenue per Share of ARS5,053.44 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AbbVie and its competitors.
Is AbbVie's Cyclically Adjusted Revenue per Share too high?
AbbVie's current Cyclically Adjusted Revenue per Share is ARS5,053.44. Overall, AbbVie has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Cyclically Adjusted Revenue per Share compare to MRK and JNJ?
AbbVie's Cyclically Adjusted Revenue per Share of ARS5,053.44 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AbbVie and its competitors. AbbVie's current Cyclically Adjusted Revenue per Share is ARS5,053.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (BUE:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is ARS34,303.45, compared to a current price of ARS38,780.00 — trading 13% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ARS5,053.44. AbbVie's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AbbVie (BUE:ABBV), the current Cyclically Adjusted Revenue per Share is ARS5,053.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (BUE:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of ARS38,780.00 is trading 13% above its estimated GF Value™ of ARS34,303.45. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for BUE:ABBV:

  • Cyclically Adjusted Revenue per Share: ARS5,053.44
  • GF Value™: ARS34,303.45 vs. price of ARS38,780.00 (13% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the BUE:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
67GF Score

Get the complete analysis for BUE:ABBV

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS38,780.00
Price
ARS34,303.45
GF Value